Vaccination against helminth IL-33 modulators permits immune-mediated parasite ejection

Area of Science:

• Immunology
• Parasitology
• Vaccine Development

Background:

• Heligmosomoides polygyrus bakeri (Hpb) uses proteins like HpARI and HpBARI to suppress host immunity.
• These immunomodulatory proteins target key immune signaling pathways, including IL-33 and its receptor ST2.
• The effects of Hpb immunomodulation are localized and systemic, particularly within the first week of infection.

Purpose of the Study:

• To investigate the efficacy of vaccination with Hpb immunomodulatory proteins (HpARI and HpBARI) in modulating host immune responses.
• To determine if antibodies generated against HpARI and HpBARI can neutralize their immunosuppressive functions.
• To assess the protective potential of a combined vaccine strategy against Hpb infection.

Main Methods:

• Vaccination of mice with recombinant HpARI or HpBARI proteins.
• Analysis of immune cell populations, including type 2 innate lymphoid cells (ILC2s) and T helper 2 (Th2) cells.
• Measurement of cytokine levels (IL-4, IL-5) and antibody responses.
• Assessment of parasite burden, egg counts, and intestinal pathology post-infection.

Main Results:

• Vaccination with HpARI2 increased ILC2s, Th2 cells, and serum IL-4/IL-5.
• HpBARI + HpBARI_Hom2 vaccination restored ST2 function and enhanced Th2 immunity.
• A combination vaccine (HpARI2 + HpBARI + HpBARI_Hom2) conferred robust protection, reducing parasite size, egg burden, and promoting goblet cell hyperplasia.

Conclusions:

• Vaccination strategies targeting parasite-derived immunomodulatory proteins are effective in controlling Hpb infection.
• Antibodies generated against HpARI and HpBARI can neutralize their immune-suppressive activities.
• This approach offers a promising avenue for developing vaccines against parasitic helminth infections by blocking key parasite immune evasion mechanisms.